Oxford Asset Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Oxford Asset Management’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-41,886	Closed	-$1.36M	–	1576
2019 Q4	$1.36M	Sell	41,886 -32,774	-44%	-$1.02M	0.04%	657
2019 Q3	$1.94M	Buy	74,660 +25,567	+52%	+$856K	0.05%	564
2019 Q2	$1.8M	Buy	49,093 +27,185	+124%	+$651K	0.04%	687
2019 Q1	$484K	Sell	21,908 -14,850	-40%	-$260K	0.01%	1230
2018 Q4	$518K	Buy	36,758 +14,038	+62%	+$219K	0.01%	1184
2018 Q3	$438K	Buy	22,720 +6,259	+38%	+$128K	0.01%	1352
2018 Q2	$380K	Buy	+16,461	New	+$384K	0.01%	1436

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Oxford Asset Management's ODT Position: Q1 2020 in Review

Oxford Asset Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2020, closing a stake of 41,886 shares — an estimated $1.36M sold.

Oxford Asset Management first reported a position in ODT in Q2 2018 and held it in 7 quarters. The position peaked at $1.94M in Q3 2019. 78 funds tracked by Wall St. Rank hold ODT as of Q1 2020.

Oxford Asset Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 41,886 Odonate Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $1.36M.
Oxford Asset Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2018 and held it in 7 quarters.
Oxford Asset Management's Odonate Therapeutics, Inc. Common Stock position peaked at $1.94M in Q3 2019.
78 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.